References
- Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681–90
- Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 2002; 14(1)47–57
- Swartz MS, Perkins DO, Stroup TS, McEvoy JP, Nieri JM, Haak DC. Assessing outcomes and functional outcomes in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project schizophrenia trial. Schizophr Bull 2003; 29: 33–43
- Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New Engl J Med 2005;353:1209–23.
- Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia:?Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079–87
- Haro JM, Suarez D, Novick D, Brown J, Usall J, Naber D, and the SOHO study group. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur J Neuropsychopharmacol 2007;17(4):235–44.
- Tiihonen J, Wahlbeck K, Lonnqvist J, Klaukka T, Ioannidis JPA, Volavka J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. Br Med J 2006; 333: 224–7
- Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad effectiveness trial with aripiprazole (BETA). Schizophrenia Res 2006; 84: 77–89
- Kasper S. First-episode schizophrenia: The importance of early intervention and subjective tolerability. J Clin Psychiatry 1999; 60(Suppl 23)5–9
- Taylor DM, Atkinson J, Fischetti C, Sparshatt A, Jones S. A prospective 6 month analysis of the naturalistic use of aripiprazole – factors predicting favourable outcome. Acta Psychiatr Scand 2007; 116: 461–466
- Christensen AF, Poulsen J, Nielsen CT, Bork B, Christensen A, Christensen M. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study. Acta Psychiatr Scand 2006; 113: 148–53
- Kane JM, Meltzer H, Carson WH, Jr, McQuade RD, Marcus RN, Sanchez R, for the Aripiprazole Study Group. Aripiprazole for treatment resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007;68:213–3.
- Patel MX, Young C, Samele C, Taylor DM, David AS. Prognostic indicators for early discontinuation of risperidone long-acting injection. Int Clin Psychopharmacol 2004; 19(4)233–9
- Taylor DM, Young C, Patel MX. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int J Neuropsychopharmacol 2006; 9: 685–94
- Deslandes PN, Thomas A, Faulconbridge GM, Davies WC. Experience with risperidone long acting injection: results of a naturalistic observation study. Int J Psychiatry Clin Pract 2007; 11(3)207–11